Avalon Pharmaceuticals to Release Fourth Quarter and Full Year 2007 Results
March 12 2008 - 4:58PM
Business Wire
Avalon Pharmaceuticals, Inc. (Nasdaq:AVRX), today announced that it
is scheduled to release financial results for the fourth quarter
and full year of 2007 on Wednesday, March 19, 2008 after the close
of the U.S. financial markets. The Company will also host a
conference call on Thursday, March 20, 2008 at 8:30 a.m. Eastern
Time to discuss its business and financial results, as well as
future expectations. Interested investors, analysts, members of the
media and the general public can listen to the call live over the
Internet or by dialing the numbers listed below. Conference Call
details: Dial-In: (888) 287-5529 (U.S.) (719) 457-2088
(International) Passcode: 5811984 � Webcast: Please visit the
Investor Presentations section of Avalon Pharmaceuticals' website,
http://www.avalonrx.com. � The conference call replay will be
available for 30 days. About Avalon Pharmaceuticals Avalon is a
biopharmaceutical company focused on the discovery, development and
commercialization of first-in-class cancer therapeutics. Avalon�s
lead product candidate, AVN944,�an IMPDH inhibitor, is in Phase II
clinical development. Avalon also has preclinical programs to
develop inhibitors of the Beta-catenin and Aurora/Centrosome
pathways,�discovery programs�for�inhibitors of�the Survivin�and
Myc�pathways and partnerships with Merck, MedImmune, ChemDiv,
Medarex, and Novartis. AvalonRx� is the company�s proprietary
platform�which is based on�large-scale�biomarker identification and
monitoring, used to discover and develop therapeutics for pathways
that have historically been characterized as "undruggable." Avalon
is headquartered in Germantown, MD.
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Avalon (NASDAQ:AVRX)
Historical Stock Chart
From Jul 2023 to Jul 2024